ArticleOncoTargets and therapy2019
Irreversible electroporation combined with chemotherapy for unresectable pancreatic carcinoma: a prospective cohort study.
Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Folate Intake and Risk of Pancreatic Cancer: A Systematic Review and Updated Meta-Analysis of Epidemiological Studies.Digestive diseases and sciences · 2021Pooled it
- Outcomes of Irreversible Electroporation for Treatment of Refractory Locally Advanced Pancreatic Cancer.Journal of vascular and interventional radiology : JVIR · 2026Article
- Novel Combination of Irreversible Electroporation and Allogenic Chimeric Antigen Receptor T-Cell Therapy Synergizes Therapeutic Outcomes in a Preclinical Human Pancreatic Cancer Mouse Model.Research (Washington, D.C.) · 2026Article
- Exceptional Response to Multimodal Therapy in Stage IV Pancreatic Ductal Adenocarcinoma: A Case Report and Review.Cureus · 2025Article
- Pulsed field ablation in medicine: irreversible electroporation and electropermeabilization theory and applications.Radiology and oncology · 2025Review
- Pancreatic cancer: failures and hopes-a review of new promising treatment approaches.Exploration of targeted anti-tumor therapy · 2025Review
- Comparison of Chemotherapy Combined with Percutaneous Electroporation and Chemotherapy Alone in the Management of Locally Advanced Gallbladder Carcinoma (GBC): A Study Protocol.Cardiovascular and interventional radiology · 2024Article
- Irreversible Electroporation in Pancreatic Cancer-An Evolving Experimental and Clinical Method.International journal of molecular sciences · 2023Review
- Safety and feasibility of irreversible electroporation for the pancreatic head in a porcine model.World journal of gastrointestinal oncology · 2022Article
- Article
- Local ablation of pancreatic tumors: State of the art and future perspectives.World journal of gastroenterology · 2021Review
- Ablation in Pancreatic Cancer: Past, Present and Future.Cancers · 2021Review
- Irreversible Electroporation (IRE) in Locally Advanced Pancreatic Cancer: A Review of Current Clinical Outcomes, Mechanism of Action and Opportunities for Synergistic Therapy.Journal of clinical medicine · 2021Review
- Irreversible electroporation for liver metastasis from pancreatic cancer: A case report.World journal of clinical cases · 2020Article
- Comparison of Survival Between Irreversible Electroporation Followed by Chemotherapy and Chemotherapy Alone for Locally Advanced Pancreatic Cancer.Frontiers in oncology · 2020Article
- Irreversible Electroporation: Background, Theory, and Review of Recent Developments in Clinical Oncology.Bioelectricity · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe aimed to determine the safety and efficacy of irreversible electroporation (IRE) combined with chemotherapy for unresectable pancreatic carcinoma (stage III/IV).
methodsWe prospectively enrolled 54 patients (30 men; median age 61.0 years; range 41-73 years) undergoing IRE with or without chemotherapy for pancreatic cancer between July 2015 and August 2016. Kaplan-Meier estimates were used to analyze progression-free survival (PFS) and overall survival (OS). Safety was assessed based on the occurrence of adverse events.
resultsAll patients successfully underwent IRE. Major IRE-related complications were observed in four patients (7.4%). Gastrointestinal hemorrhage only developed in cases undergoing IRE via the open method, and was successfully managed with interventional embolization and/or vascular ligation. Any minor complications in the cases were alleviated within 14 days after symptomatic treatment. Overall, the performance status score decreased from 1.06 to 0.89 at 3 months after IRE (
conclusionPatients with pancreatic carcinoma could benefit from IRE, which improved the OS in certain patients who had also undergone chemotherapy. Although some severe complications were noted, IRE was generally well tolerated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.